Out of curiosity, did you actually see any pharma ads on OpenEvidence?
Users have noted that some current tools heavily overweight citations from 'Partner Journals' (like NEJM/JAMA) because they index the full text, effectively burying better papers from non-partner journals in the vector retrieval.
My goal is strictly Neutral Retrieval. By hitting the PubMed/OpenAlex APIs live, Evidex treats a niche pediatric journal with the same relevance weight as a major publisher, ensuring the 'Long Tail' of evidence isn't drowned out by business partnerships.
> $150M RR on just ads, +3x from August. On <1M users.
Thanks for sharing that source. It really validates the thesis that unless the user pays (SaaS), the Pharma companies are the real customers.
You are definitely right that Live APIs come with their own headaches (mostly latency and rate limits).
For now, I chose this path to avoid the infrastructure overhead of maintaining a massive fresh index as a solo dev. However, I suspect that as usage grows, I will have to move toward a hybrid model where I cache or index the 'head' of the query distribution to improve performance.
Always great to meet others tackling this space. I’d love to swap notes sometime if you are open to it.